Modeling Human Diseases in C. elegans group
CRISPR GENOME EDITING
Its short life cycle, its hermaphroditism, and its syncytial germline are advantages to use C. elegans as model to develop CRISPR technologies. We investigate most efficient and versatile methodologies to edit genetic locus in animals.
RNA AND DISEASE
Mechanisms of RNA processing are highly conserved from yeast to humans and are frequently altered in human diseases. We use the powerful C. elegans genetics to study RNA-related processes that are impaired in diverse diseases as cancer or retinitis pigmentosa.
CHEMORESISTANCE TO CISPLATIN
Tumors can become resistant to chemotherapeutical agents, limiting the effectiveness of the treatment. We take advantage of the toxicity of cisplatin on C. elegans to study the molecular and celular mechanisms that confer both resistance and sensitivity to chemotherapy.
Mimicking of splicing-related retinitis pigmentosa mutations in C. elegans allow drug screens and identification of disease modifiers.
Kukhtar D*, Rubio-Peña K*, Serrat X, Cerón J.*
Human Molecular Genetics. 2020 Jan 10. pii: ddz315.
CRISPR editing of sftb-1/SF3B1 in C. elegans allows the identification of synthetic interactions with cancer-related mutations and the chemical inhibition of splicing.
Xènia Serrat, Dmytro Kukhtar, Eric Cornes, Anna Esteve-Codina, Helena Benlloch, Germano Cecere, Julián Cerón*
PLoS Genetics, October 2019 ; https://doi.org/10.1371/journal.pgen.1008464
Efficient Generation of Endogenous Fluorescent Reporters by Nested CRISPR in Caenorhabditis elegans.
Vicencio J, Martínez-Fernández C, Serrat X, Cerón J.*
Genetics. 2019 Apr;211(4):1143-1154.
Genetic and cellular sensitivity of Caenorhabditis elegans to the chemotherapeutic agent cisplatin.
García-Rodríguez FJ, Martínez-Fernández C, Brena D, Kukhtar D, Serrat X, Nadal E, Boxem M, Honnen S, Miranda-Vizuete A, Villanueva A, Cerón J.*
Disease Models and Mechanisms, 2018 Jun 21;11(6).
phone: +34 93 260 7287
email: firstname.lastname@example.org, email@example.com